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Abstract 
Introduction 
Systemic-onset juvenile idiopathic arthritis (SoJIA) is a potentially severe disease with both 
systemic and joint inflammation; different evolutive forms were described (monophasic, 
polyphasic or persistent), but the outcome is hardly predictable at diagnosis.  
This study aims to identify early predictors of disease evolution within the SoJIA population 
enrolled in the Juvenile Inflammatory Rheumatism cohort (JIRcohorte), an international 
prospective cohort study. 
 
Method 
104 SoJIA patients with a minimum of two-year follow-up were enrolled. 59 patients were 
excluded due to loss to follow-up, consent withdrawal or incomplete information on disease 
activity. Demographics, clinical data and disease activity were collected (retrospectively if 
diagnosis < 2015 and prospectively if diagnosis ≥ 2015) and described for 45 patients. At 
diagnosis, median age and disease duration was 4.75 years and 1.0 months, respectively, 
male to female ratio was 1:1.6. Median follow-up was 5.02 years. 41 and 31 patients were 
treated with biologics and Disease Modifying Anti-Rheumatic Drugs (DMARDs), respectively.  
We present the results in 45 patients with complete data for disease activity and medication 
use.  
 
Results 
Corresponding to their evolution, patients were classified in the monophasic (n=12), polyphasic 
(n=17) or persistent group (n=16). Females were predominant in the monophasic and 
polyphasic group with 91.7% and 58.8%, respectively. Initial clinical presentation was 
characterized by fever for nearly all children (97.8%), other systemic symptoms were much 
less frequent. Possible predictors were first analyzed by univariate logistic regression 
comparing persistent disease evolution with non-persistent disease evolution (i.e. monophasic 
and polyphasic). Polyarthritis at 6-months and arthritis at 12-months post-diagnosis was both 
significantly more frequent in the persistent disease evolution group 18.8% vs. 3.4%; p < 0.05 
and 56.3% vs. 13.8%; p < 0.01, respectively. Patients having a delay between symptom onset 
and diagnosis (> 2 months) were significantly more frequent in the persistent disease evolution 
group. The rate of elevated laboratory inflammatory markers at 6- and 12- months was 
significantly higher in the persistent group as well (ESR ≥ 26 mm/h: 37.5% vs. 3.4%, p < 0.01; 
CRP > 10 mg/L: 62.5% vs. 13.8%, p < 0.01). Furthermore, the treatment frequency with 
DMARDs and the treatment duration of more than six months was both significantly higher in 
the persistent group 93.8% vs. 55.2%; p < 0.05 and 93.7% vs 41.4%; p < 0.05, respectively.  
 
Conclusion 
Active arthritis as well as elevated inflammatory markers throughout the first year of disease 
are possible predictors of a persistent disease course. Furthermore, the delay between 
symptom onset and diagnosis (> 2 months) is suggesting a persistent disease evolution. The 
persistent disease evolution correlates with a more severe disease course. Therefore, it is 
expectable that the type of medication used, and its duration are more severe as well. The 
multivariate model did not show any statistically significant difference between the persistent 
vs. non-persistent group. We have further validated the existence of three clinically discernable 
disease evolution types in SoJIA, which may be predicted at diagnosis by several clinical 
features. Further research should concentrate on standardized data collection in multicenter 
cohort studies to generate enough statistical power to confirm or reject the presented 
tendencies within this study.   
 
Keywords: systemic juvenile idiopathic arthritis; disease evolution; outcome  
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Introduction 
Historical preamble. In 1897 George Frederic Still published the first description of, what we 
know today as, systemic-onset juvenile idiopathic arthritis (SoJIA). The eponymous “Still’s 
disease” endures in the name for its adult-onset form (adult-onset Still’s disease, AOSD). In 
his work “On a form of chronic joint disease in children”, he painted a detailed picture of the 
clinical presentation of twelve patients with articular inflammation, splenomegaly and 
lymphadenopathies. He was also the first to comment on the disease course of SoJIA, 
concluding that: “The course of these cases is slow. Improvement may occur for a time under 
treatment or spontaneously, but the disease soon progresses again until a condition of general 
joint disease is reached which seems to be permanently stationary.”(1)  
 
Classification. SoJIA is categorized among a heterogeneous group of pathologies termed 
“juvenile idiopathic arthritis” (JIA) which includes all pediatric rheumatic diseases of unknown 
origin that present with a persistent (> six weeks) arthritis before the age of sixteen years. At 
the beginning of the 21st century, the International League of Associations for Rheumatology 
(ILAR) classified seven JIA subtypes in the aim of creating a common nomenclature. The 
seven subtypes are Systemic Arthritis (SoJIA), Oligoarthritis, Polyarthritis (Rheumatoid Factor 
Negative), Polyarthritis (Rheumatoid Factor Positive), Psoriatic Arthritis, Enthesitis Related 
Arthritis, Undifferentiated Arthritis. SoJIA is distinguished from other JIAs due to its particularity 
of having a variety of systemic symptoms. To fulfill the ILAR criteria for SoJIA, the patient 
should present a persistent (> two weeks) undulating fever with a paroxysmal pattern, 
accompanied by oligo- or polyarthritis and either rash, lymphadenopathy, serositis (i.e. 
pericarditis, pleuritis or peritonitis) or organomegaly (hepato- and/or splenomegaly).(2) 
Patients are also at risk of developing potentially fatal systemic inflammatory complications 
(such as macrophage activation syndrome(3)), which has resulted in SoJIA having the highest 
mortality rate (3.9/1000 person years (4)) of all JIA subtypes.  
 
Despite recent medical advances, SoJIA remains a diagnosis by exclusion, where its 
heterogeneous and nonspecific clinical presentation, as well as the lack of specific laboratory 
markers, create difficulties for a rapid and accurate diagnosis. SoJIA reportedly accounts for 
10% of all JIA cases in Europe, however its impact is likely under-represented due to these 
problematic diagnostic criteria (5,6). 
 
Clinical presentation. Behrens et al. studied the clinical presentation of SoJIA in 136 children 
and found significant variation among initial presentations of the case-defining symptoms, 
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which could range from isolated occurrences of a single symptom to various, life-threatening 
combinations. However, only a small percentage presented with the ILAR criteria necessary 
for SoJIA classification: a weakness that was already reported by Hofer et al. in 2001.(7) The 
most frequent symptoms at first presentation were fever followed by arthritis and cutaneous 
rash, all diagnosed in over 75% of the children included. Lymphadenopathies, organomegalies 
and pericarditis were seen in much fewer patients. Articular involvement was oligo- or 
polyarticular in over 80% of cases, whereas the most frequent joints involved were the wrists, 
knees and ankles.(8) 
 
Cytokine profile. SoJIA is a complex autoinflammatory disease with a cardinal implication of 
the innate immune system. Neutrophils, monocytes and macrophages are predominantly 
activated, resulting through different pathways in the excess of pro-inflammatory cytokines, 
mostly Interleukin 1β (IL-1β), Interleukin 18 (IL-18) and Interleukin 6 (IL-6). IL-1β has a well-
known pro-inflammatory activity. In 2001, Pascual et al. documented the overexpression of IL-
1β in SoJIA by showing its secretion from healthy Peripheral Blood Mononuclear Cells (PBMC) 
after incubation with the serum of SoJIA patients. (9) Furthermore, the efficacy of anti-IL1 drugs 
underlines the important role of this cytokine in the pathophysiology of SoJIA. (10,11) In 
addition, anti-IL6 treatment has a well reported efficacy in SoJIA patients, supporting its 
implication in the disease. (12,13) IL-18, a proinflammatory cytokine of the IL-1 family, has a 
crucial role in the pathophysiology of SoJIA. Lotito et al. showed much higher levels of IL-18 
in synovial fluid of SoJIA patients compared to other JIA patients. (14) Furthermore, Weiss et 
al. proposed an association between the macrophage activation syndrome, a potentially fatal 
complication of SoJIA, and chronically elevated IL-18 levels. (15) Interleukin 10 (IL-10) has an 
anti-inflammatory role and hypotheses are, that IL-10 may be defective or insufficient in SoJIA 
patients, failing to counterbalance the pro-inflammatory mechanism.(16) Interleukin 17 (IL-17), 
Tumor necrosis factor-α (TNF-α) and Interferon-γ (INF- γ) are cytokines that are implicated 
with an undetermined or controversial role in the pathophysiology of SoJIA. (17,18)  
 
Treatment. First-line therapies include Non-Steroidal Anti-Inflammatory Drugs (NSAID) and 
glucocorticoids. In recent years, great advances have been made in identifying the potential 
mediators of the underlying immunological pathology, such as IL-1β and IL-6. (9,19) Biological 
agents targeting these immune pathways have since shown promise in several randomized 
controlled clinical trials. Notably, Anakinra (Anti-IL 1 receptor-antagonist), Canakinumab (Anti-
IL1β antibody) and Tocilizumab (Anti-IL6R antibody), which have all since been incorporated 
into the standard therapeutic SoJIA regimen. (10–12) Current research concentrates on 
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identifying new cytokine targets, such as the inhibition of Interleukin 18 (IL-18), an important 
pro-inflammatory cytokine of the IL-1 family. Recent results of the first clinical study testing the 
recombinant human IL-18 binding protein in adults showed good response and a favorable 
safety profile in AOSD patients. (20) Today’s research is concentrated on evaluating not only 
their efficacy but also their safety by designing prospective cohort studies enabling long term 
monitoring of adverse effects that were not captured in the shorter efficacy studies. (13,21,22)  
 
Disease evolution and outcome. Morbidity in SoJIA is largely defined by the functional 
limitations of destructive arthritis. Spiegel et al. identified thrombocytosis and persistent active 
systemic disease (six months after onset) as strong predictors for a poor functional outcome. 
(23) Persistent active systemic disease has proven to be a particularly important prognostic 
marker. (24,25) Lomater et al. first described the different patterns of disease evolution as 
monocyclic, intermittent and persistent. (24) Singh-Grewal et al. are one of the few groups to 
examine the predictors of the disease evolution in SoJIA. According to them, the only factor at 
diagnosis that is predictive of a non-monophasic (i.e. intermittent or persistent) evolution was 
the presence of a polyarticular arthritis. They described additional predictors of a non-
monophasic course at three months (i.e. fever and active arthritis) and six months post 
diagnosis (i.e. erythrocyte sedimentation rate (ESR) > 26 mm/hour and the persistent use of 
corticosteroids).(26) So far, our knowledge of the early predictors in SoJIA disease evolution 
is based on very limited data, which is fractured across groups with varying diagnostic 
definitions.  
 
Objectives. This retrospective cohort study aims to identify early predictors of SoJIA disease 
evolution using standardized classifications. We provide detailed diagnostic phenotypes of 45 
enrolled patients including clinical, laboratory and treatment variables. We then examine 
univariate and multivariate correlations of these variables with the disease progression. The 
second aim is to describe the disease evolution within this international SoJIA population.  
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Materials and methods 
Cohort and study design. A multicenter retrospective observational study was conducted on 
45 patients enrolled in the Juvenile Inflammatory Rheumatism cohort (JIRcohorte). 104 
patients were recruited and followed at the participating pediatric rheumatology tertiary referral 
centers (Pediatric Immunology and Rheumatology Romande (n=17), University Children's 
Hospital Zurich (n=9), Lugano Regional Hospital (n=1), Children’s Hospital Ibnou Rochd 
Casablanca (n=15), Hôpital Femme Mère Enfant University Hospital Lyon (n=33), Hôpital 
d'Estaing, University Hospital Clermont-Ferrand (n=6), University Hospital Nantes (n=2), 
University Hospital Leuven (n=21). 
Patients were considered eligible if diagnosed as having SoJIA using an expert opinion and/or 
the ILAR criteria(2) and complete information on disease activity. Signed informed consent 
was provided by all legal guardians and by older children with age-adapted consent forms. 
Inclusion required a minimum two-year follow-up participation. 42 patients were excluded due 
to consent withdrawal or loss-to-follow-up. Seventeen patients were excluded due to 
incomplete information on disease activity. Expert opinion is defined as high clinical and 
laboratory suspicion of SoJIA by an experienced pediatric rheumatologist without fulfilling all 
necessary ILAR criteria.  
The JIRcohorte is an observational prospective inception cohort study developed to promote 
multicentric international studies on juvenile inflammatory rheumatisms aiming a better 
understanding of these rare diseases and their therapies. More than twenty participating 
centers in France, Switzerland, Belgium and Morocco contribute to the data collection. 
Prospective data collection started in 2015. Patients are enrolled when having a juvenile 
inflammatory rheumatism and a signed informed consent.  
 
Data collection. Data, concerning information from 2005 until 2014, was systematically 
collected in the JIRcohorte platform by consulting patient dossiers. Data concerning 
information from 2015 until August 2018 was prospectively entered in the JIRcohorte platform. 
Missing data from 2015 until 2018 was retrospectively entered by consulting patient dossiers.  
Data collected included demographic information such as sex, origin, age at disease onset, 
and age at diagnosis. Clinical signs and symptoms included joint count (i.e. number of joints 
with arthritis), and binary variables for the presence of enthesitis, arthralgia, fever, rash, 
lymphadenopathy, hepatomegaly, splenomegaly and serositis. Additionally, laboratory results 
[Elevated Sedimentation Rate (ESR), C reactive protein (CRP)] and detailed medication use 
were also captured. 
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Disease evolution was observed at 6 months post-diagnosis and then annually by following 
the assessment of the disease status by the pediatric rheumatologist (i.e. classification into 
either inactive disease, continued activity or flare). Clinically inactive disease is defined using 
the following criteria proposed by Wallace et al.: absence of systemic symptoms (fever, rash, 
organomegaly, or generalized lymphadenopathy), absence of active arthritis and uveitis, 
normal ESR or CRP results, physician’s global assessment of disease activity at the best 
possible score for the instrument used (e.g. Visual Analogue Scale at 0 cm) and duration of 
morning stiffness of ≤ 15 minutes. (27) A flare is defined as reoccurrence of one of the 
previously defined variables. Remission is defined as twelve months of clinically inactive 
disease. (28) The monophasic disease course in this study is defined as the occurrence of 
active disease (systemic symptoms and/or arthritis) followed by inactive disease without 
recurrence. By this definition, remission is obtained within 2 years. The polyphasic course is 
defined by the recurrence of active disease at any time after having achieved inactive disease. 
A persistent evolution is characterized by the persistence of systemic symptoms and/or arthritis 
and/or abnormal laboratory results for at least 24 months. 
 
Primary data analysis. 
Demographic and clinical data were summarized by their frequencies and percentages. 
Continuous variables are represented by their medians and interquartile range.  
Analysis of variance (ANOVA) was performed to assess differences of clinical, laboratory and 
therapy features between the three disease evolution groups (i.e. monophasic, polyphasic and 
persistent).  
Univariate and multivariate logistic regression was performed to assess the association 
between each predictor and the outcome of persistent disease evolution at diagnosis, 6 
months and 12 months post diagnosis. Associations are reported as p-values with 95% 
confidence intervals. Predictors with continuous variables were grouped (e.g. Delay from 
disease onset to diagnosis ≤ 2 months or > 2month, time from diagnosis to inactive disease ≤ 
6 months or > 6 months, age at diagnosis and age at first symptoms < 5 years or ≥ 5 years, 
ESR < 26 mm/h or ≥ 26 mm/h, CRP ≤ 10 mg/L or > 10 mg/L, treatment duration < 6 months 
or ≥ 6 months for biologic agents, DMARDs and glucocorticoids). 
Kaplan-survival curves were created for each disease evolution type (i.e. monophasic, 
polyphasic and persistent) to assess the cumulative probabilities of attaining inactive disease 
as well as active joint count 0. Active joint count is defined as either a swelling, or a limitation 
of the range of motion with pain or tenderness.(2) 
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Results 
Demographics, clinical and laboratory characteristics. 45 patients with a median age of 
4.75 years at diagnosis were included. 62% were females. The median delay between 
symptom onset and diagnosis was four weeks. First description of inactive disease was made 
after a median period of 18 months. The median follow-up was 5 years. The origin of patients 
and further demographic characteristics are shown in table 1.  
 
 
Median (25-75 percentiles) if not otherwise specified 
 
  
Table 1 Demographics of study cohort 
 All Monophasic Polyphasic Persistent 
Number of patients 45 12 17 16 
Female (%) 62.2 91.7 58.8 43.8 
Age at diagnosis in years  4.75 (2.4 – 8.6) 8.87 (5.4 – 13.2) 3.64 (1.6 – 6.5) 4.35 (2.7 – 7.2) 
Disease duration at diagnosis in 
months  
1.00 (0 .25- 
1.75) 
1.00 (0 – 3.5) 1.00 (0 – 60) 5.50 (1.0 – 8.0) 
Time to follow-up in years   5.02 (3.3 – 8.7) 3.6 (2.7 – 5.0) 5.1 (3.3 – 6.9) 8.7 (4.5 – 10.1) 
Country of birth (% of patients) 
France 
Morocco  
Portugal 
Spain 
Suisse 
Unknown 
 
6.7 
26.7 
2.2 
2.2 
15.6 
46.7 
 
8.3 
0 
8.3 
0  
25 
58.3 
 
5.9 
23.5 
0 
5.9 
11.7 
52.9 
 
6.25 
50 
0 
0 
12.5 
31.2 
Country of follow-up (% of 
patients) 
Belgium 
France 
Morocco 
Suisse 
 
 
18 
24 
27 
31 
 
 
17 
25 
0 
58 
 
 
18 
29 
24 
29 
 
 
19 
19 
50 
12 
Time to Inactive disease in 
months 
18 (6 – 46) 12 (3.25 – 20.25) 6 (3 – 18) 62.5 (39.25 – 85.25) 
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Corresponding to their disease evolution, patients were classified in monophasic (n=12; 
26.7%), polyphasic (n= 17; 37.8%) or persistent (n=16; 35.6%) disease evolution groups. The 
persistent disease evolution group showed two particularities concerning demographic 
features compared to the other disease courses: The time to diagnosis was five times longer 
and the duration of active disease until the first description of inactive disease was over 5 years 
in this group.   
Initial clinical presentation was characterized by fever for all three disease evolution groups. 
Other systemic symptoms such as cutaneous rash and splenomegaly were less frequent but 
showed differences in prevalence between the three evolution groups – rash and 
organomegaly were more prevalent in the monophasic and polyphasic disease evolution 
groups than in the persistent group. Serositis, on the other hand, was diagnosed more 
frequently in the polyphasic (23.5%) and the persistent (12.5%) disease evolution groups, no 
patient from the monophasic group presented with serositis. Arthritis at diagnosis was seen in 
all patients from the persistent disease evolution group, and in 75% and 94.1% of the 
monophasic and the polyphasic patients, respectively. Oligoarthritis during the first 6 months 
of disease was observed in 58.8% of the polyphasic patients, whereas polyarthritis was found 
in 75% of the persistent disease evolution patients. During disease course, 87.5% of the 
patients with persistent disease evolution presented a polyarticular arthritis. Inflammatory 
laboratory markers, such as Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein 
(CRP), varied across disease groups. Median ESR values at diagnosis were the highest in the 
persistent group with 90 mm/h and the lowest in the monophasic group with 71 mm/h. CRP 
values were the most elevated in the polyphasic group with 115.5 mg/L followed by the 
persistent disease evolution category with 100.5 mg/L and were much lower in the monophasic 
group with 34 mg/L. Median values of ESR and CRP for the whole study population as well as 
more detailed information on the results including interquartile ranges are shown in table 2.   
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Table 2 Clinical and laboratory characteristics at diagnosis  
Number of patients (%) 
All  
(n = 45) 
Monophasic 
(n=12) 
Polyphasic  
(n=17) 
Persistent  
(n=16) 
Fever  44 (97.8%) 12 (100%) 17 (100%) 15 (93.8%) 
Rash  30 (65.2%) 9 (75%) 12 (70.6%) 9 (56.3%) 
Lymphadenopathy  18 (40%) 4 (33.3%) 7 (41.2%) 7 (43.8%) 
Hepatomegaly  8 (17.8%) 2 (16.7%) 3 (17.6%) 3 (18.8%) 
Splenomegaly  9 (20%) 4 (33.3%) 3 (17.6%) 2 (12.5%) 
Serositis  6 (13.3%) 0 (0%) 4 (23.5%) 2 (12.5%) 
Arthralgia  16 (35.5%) 7 (58.3%) 6 (35.3%) 3 (18.8%) 
Arthritis at any moment of 
disease 
41 (91.1%) 9 (75%) 16 (94.1%) 16 (100%) 
Joint count during first 6 months 
1-4 joints 
5+ joints 
 
16 (35.5%) 
23 (51.1%) 
 
4 (33.3%) 
4 (33.3%) 
 
8 (58.8%) 
7 (41.2%) 
 
4 (25%) 
12 (75%) 
Joint count during disease 
course (after first 6 months) 
1-4 joints 
5+ joints 
 
 
12 (26.6%) 
26 (57.5%) 
 
 
3 (25%) 
4 (33.3%) 
 
 
7 (41.2%) 
8 (58.8) 
 
 
2 (12.5%) 
14 (87.5%) 
ESR [mm/h]  77 (40 – 100) 71 (22.7 – 86) 88 (59 – 120) 90 (32 – 109.5) 
CRP [mg/L] 90 (23.5 – 
120.5) 
34 (8 – 87.2) 115.5 (12.5 – 
138.5) 
100.5 (70.1 – 
158.7) 
Median (25-75 percentiles) if not otherwise specified 
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Treatment. All patients were treated with Non-steroidal Anti-inflammatory Drugs (NSAID) and 
nearly all with glucocorticoids. All children in the polyphasic and persistent groups and 66% of 
the monophasic group were treated with biologic agents. Biologic agents used in this SoJIA 
population were Abatacept (CTLA4-Ig), Adalimumab (Anti-TNF-α), Anakinra (Anti-IL 1 
receptor-antagonist), Canakinumab (Anti-IL1β antibody), Etanercept (Anti-TNF-α), Rituximab 
(Anti-CD20 antibody), Tocilizumab (Anti-IL6R antibody). Disease Modifying Anti-Rheumatic 
Drugs (DMARD) were used in 93.8%, 70.6% and 33.3% of the persistent, the polyphasic and 
the monophasic patients, respectively. The DMARDs used were Methotrexate and Ciclosporin. 
Detailed information on the number of patients treated with biologics, glucocorticoids, NSAID 
and DMARDs as well as information on treatment duration are shown in table 3.  
  
Table 3 Treatment of study cohort 
Number of patients (%) 
All  
(n = 45) 
Monophasic 
(n=12) 
Polyphasic  
(n=17) 
Persistent  
(n=16) 
Biologics  41 (91.1%) 8 (66.7%) 17 (100%) 16 (100%) 
Glucocorticoids 43 (95.6%) 12 (100%) 15 (88.2%) 16 (100%) 
NSAID  35 (77.8%)* 7 (58.3%) 13 (76.5%) 15 (93.8%) 
DMARD 31 (68.9%) 4 (33.3%) 12 (70.6%) 15 (93.8%) 
Median treatment duration in years 
(range) for patients under: 
Biologics 
Glucocorticoids 
NSAID 
DMARD 
 
 
3.6 (0 – 12.8) 
1.4 (0 – 10.1) 
0.8 (0 – 10.5) 
1.1 (0 – 13.2) 
 
 
2.2 (0 – 5.4) 
0.5 (0.1 – 1.4) 
0.06 (0 – 0.4) 
0 (0 – 4.2) 
 
 
3.3 (1.7 – 10.8) 
2.2 (0 – 7.6) 
1.1 (0 – 4.3) 
1.1 (0 – 11.8) 
 
 
6 (2 – 12.8) 
2.9 (0.9 – 10.1) 
2.8 (0 – 10.5) 
4.7 (0 – 13.2) 
* Not reported in the JIRcohorte for 15 patients 
 
Differences between monophasic, polyphasic and persistent disease evolution groups. 
Analyses of variance (ANOVA) was performed for demographic, clinical, laboratory and 
medication features at diagnosis, 6 months and 12 months. At time point “diagnosis”, 
significant differences between the three disease evolution groups monophasic, polyphasic 
and persistent were seen for the female sex (91.7%, 58.8%, 43.8% respectively; p < 0.05) and 
the median age at diagnosis (8.8 years, 3.6 years, 4.3 years respectively; p < 0.05). No 
differences were seen in the initial clinical presentation. At time point “6 months”, significant 
differences between the three evolution groups (i.e. monophasic, polyphasic and persistent) 
were seen in the mean value of disease activity evaluated with the Visual Analogue Scale 
(VAS) by physician (VAS 0.12 cm, 1.1 cm, 5.3 cm; p < 0.05) as well as by the patient (VAS 0 
P a g e  | 14 
 
 
 
                                     Michelle Wallimann                            
 
cm, 4 cm, 7.2 cm; p < 0.05). At time point “12 months”, significant differences between the 
monophasic, polyphasic and persistent group were found in clinical features, such as the mean 
number of active joints (0.12, 0.6, 4.3 joints; p < 0.001), disease activity scored by physician 
(VAS 0 cm, 1.4 cm, 6.2 cm; p < 0.001) as well as by patient (VAS 0 cm, 1.5 cm, 5.9 cm; p < 
0.05) and in laboratory features such as the mean value of the inflammatory markers ESR 
(10.6 mm/h, 10.7 mm/h, 47.1 mm/h; respectively; p < 0.05) and CRP (1.7 mg/L, 20.5 mg/L, 
82.1 mg/L; p < 0.05). Complete analysis of variance is shown in table 1, table 2 and table 3 of 
the annex. 
 
Prediction of a persistent disease evolution. Each predictor was first analyzed by univariate 
logistic regression comparing persistent disease evolution with non-persistent disease 
evolution (i.e. monophasic and polyphasic). A delay from disease onset to diagnosis for more 
than 2 months was significantly more frequent in the persistent evolution group (62.5% vs. 
24.1%; p < 0.05). There was no significant difference observed for the predictors female sex 
or age at diagnosis ≥ 5 years. Complete information on demographic features analyzed by 
univariate logistic regression are shown in table 4.  
 
Table 4 Demographic features of patients with persistent disease evolution vs. non-persistent 
evolution 
% of patients 
Persistent disease 
evolution (n=16) 
Non-persistent disease 
evolution (n=29) 
Female Gender  43.8 72.4 
Diagnosis confirmed 93.8 93.1 
Delay between disease onset and diagnosis > 2 
months 
62.5* 24.1 
Delay between diagnosis and first description of 
inactive disease > 6 months 
100 58.6 
Age at diagnosis ≥ 5 years  37.5 55.2 
Univariate logistic regression, *p-value < 0.05; **p-value < 0.01 
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Patients with a persistent evolution suffered significantly more frequently from a polyarthritis at 
6 months (18.8% vs. 3.4%; p < 0.05). At 12 months, persistent patients had significantly higher 
rates of active arthritis (56.3% vs. 13.8%; p < 0.01). The ESR measures were significantly 
more frequently found to be higher than 26 mm/h in the persistent group at 6 months (31.3% 
vs. 3.4%; p < 0.05). The rate of elevated ESR values as well as elevated CRP values at 12 
months were significantly higher in the persistent group (ESR ≥ 26 mm/h: 37.5% vs. 3.4%, p 
< 0.01; CRP > 10 mg/L: 62.5% vs. 13.8%, p < 0.01). Detailed results on all clinical features 
analyzed are shown in table 5. 
 
Table 5 Clinical features of patients with persistent disease evolution vs. non-persistent 
disease evolution 
 
Persistent disease evolution (n=16) 
Non-persistent disease evolution 
(n=29) 
% of patients Diagnosis 6 months 12 months Diagnosis 6 months 12 months 
Arthritis  
Oligoarthritis 
Polyarthritis 
Not specified 
100 
25 
75 
0 
31.3 
12.5 
18.8* 
0 
56.3** 
37.5** 
18.8 
0 
86.2 
41.4 
37.9 
6.9 
13.8 
10.3 
3.4 
0 
13.8 
13.8 
0 
0 
 Fever  93.8 0 25 100 3.4 0 
Rash 56.3 12.5 18.8 72.4 3.4 6.9 
Lymphadenopathy 43.8 0 6.3 37.9 3.4 0 
Hepatomegaly  18.8 0 0 17.2 0 0 
Splenomegaly 12.5 0 0 24.1 0 0 
Serositis 12.5 6.3 0 13.8 0 0 
ESR ≥ 26 mm/h 68.8 31.3* 37.5** 41.4 3.4 3.4 
CRP > 10 mg/L 62.5 12.5 62.5** 48.3 6.9 13.8 
Univariate logistic regression, *p-value < 0.05; **p-value < 0.01 
 
The treatment frequency with DMARD was significantly higher for the patients with persistent 
evolution (93.8% vs. 55.2%; p < 0.05). DMARD treatment duration of > 6 months was 
significantly more frequent in the persistent group (93.7% vs 41.4%; p < 0.05). More 
information on treatment features analyzed in the univariate model are shown in table 6. 
 
  
P a g e  | 16 
 
 
 
                                     Michelle Wallimann                            
 
Table 6 Treatment features of patients with persistent disease evolution vs. non-persistent 
disease evolution 
% of patients 
Persistent disease evolution (n=16) 
Non-persistent disease evolution 
(n=29) 
Biologic agents 100 86.2 
Glucocorticoids 100 93.1 
NSAID 93.8 69 
DMARD 93.8* 55.2 
Biologic treatment 
duration ≥ 6 months 
100 86.2 
Glucocorticoid treatment 
duration ≥ 6 months 
100 62 
DMARD treatment 
duration ≥ 6 months 
93.7** 41.4 
Univariate logistic regression, *p-value < 0.05; **p-value < 0.01 
 
All predictors identified as significant in the univariate model were analyzed together in the 
multivariate logistic regression analysis. The predictors included were: Delay between disease 
onset and diagnosis > 2 months, Active joint count ≥ 1 at 6 months, Arthritis at 6 months, ESR 
≥ 26 mm/h at 6 months, Active joint count ≥ 1 at 12 months, Arthritis at 12 months, VAS ≥ 1 at 
12 months, ESR ≥ 26 mm/h at 12 months, CRP > 10 mg/L at 12 months, DMARD use, DMARD 
treatment duration ≥ 6 months, NSAID treatment duration ≥ 6 months. No significant 
differences within the tested variables were found between the persistent disease evolution 
group compared to the non-persistent disease evolution group. The results of the multivariate 
logistic regression analysis are shown in the table 4 in the annex.  
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Disease outcome. The probability of attaining inactive disease at 6 months for the whole study 
cohort was 26.7%. At 12 months, 50% of the monophasic disease evolution group and 58.8% 
of the polyphasic disease evolution group achieved inactive disease (while persistent disease 
is defined by the absence of inactive disease for 24 months). At 72 months, 82.5% of the study 
cohort achieved inactive disease, 100% of the monophasic and the polyphasic group and only 
51% of the patients with persistent disease. Detailed information on the probabilities of 
attaining inactive disease are shown in Table 7. Survival curves of attaining inactive disease 
as well as attaining active joint-count=0 (JC0) are shown in figure 1.  
 
Table 7 Cumulative probabilities of attaining inactive disease at 6, 12, 24 and 72 months 
 
 
Figure 1 Kaplan-Meier survival curve: probability of attaining inactive disease in three different 
evolution groups - monophasic, polyphasic, persistent 
 
Disease evolution 
group 
             Cumulative probabilities of attaining inactive disease (number of patients still with 
active disease) 
N° patients 6 months 
   
12 months 24 months 72 months 
Whole study 
cohort 
45 0.267 (33) 0.356 (29) 0.644 (15) 0.825 (7) 
Monophasic 12 0.250 (10) 0.500 (6) 1 (0) 1 (0) 
Polyphasic 17 0.529 (8) 0.588 (7) 1 (0) 1 (0) 
Persistent 16 0 (16) 0 (16) 0.062 (15) 0.510 (7) 
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The probability of achieving JC0 at 6 months was 35.6% for the 45 patients included. For the 
16 patients of the persistent disease evolution group, 18.7% achieved JC0 at 6 months. At 2 
years post diagnosis, the majority in the polyphasic achieved inactive joint count, but 69% of 
the persistent evolution group still had active arthritis. At the last measured time point, 72 
months post diagnosis, all patients of the polyphasic groups had JC0, whereas in the persistent 
group, nearly 20% of the patients still had JC ≥ 1. Detailed information on the probabilities of 
attaining JC0 are shown in table 8. Survival curves of attaining active joint-count=0 (JC0) are 
shown in figure 2. 
 
Table 8 Cumulative probabilities of attaining active joint count = 0 at 6, 12, 24 and 72 months 
 
 
Figure 2 Kaplan-Meier survival curve: probability of attaining active joint count = 0 in three 
different evolution groups - monophasic, polyphasic, persistent 
 
Disease evolution 
group 
               Cumulative probabilities of attaining active joint count 0 (number of patients still 
with joint count ≥ 1) 
N° patients 6 months 
   
12 months 24 months 72 months 
Whole study 
cohort 
45 0.356 (29) 0.511 (22) 0.644 (15) 0.933 (3) 
Monophasic 12 0.417 (7) 0.750 (3) 1 (0) 1 (0) 
Polyphasic 17 0.471 (9) 0.588 (7) 0.824 (3) 1 (0) 
Persistent 16 0.187 (13) 0.250 (12) 0.312 (11) 0.812 (3) 
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Discussion 
Systemic-onset juvenile idiopathic arthritis is a chronic disease that can remain active over 
several years resulting in significant morbidity for young adults, and has an impact on their 
social, professional and financial future. Although it has been established that there are three 
different types of disease evolution, information on the predictors of the disease course is 
limited. The present study was designed to describe the prevalence and clinical course of the 
different disease evolution types as well as to investigate the prognostic capacity of clinical 
features to better predict a chronic evolution. Our results validated the existence of the 
previously described disease evolution types: monophasic, polyphasic and persistent 
evolution. Over a third of the cohort had a chronic course of disease, that could be classified 
as persistent. A further third had at least one relapse. These findings, in comparison to a 
prospective observational study that analyzed 45 patients treated in an academic 
rheumatology center in Canada between 1996 and 2000, did show a different distribution in 
disease evolution classifications with nearly half of the children classified in the persistent 
group and a great minority in the polyphasic group. (26) Such differences between studies 
remain extremely common due to the absence of a unified definition for inactive disease or 
remission and therefore classification of disease evolution groups cannot be standardized. For 
instance, a recent study in an Indian setting found significant differences in the percentage of 
children classified in each disease evolution category; the authors suggested that it resulted 
from a divergence in the definition of disease remission (25); moreover, they may also result 
from the bias of selection because of a non-randomization of the population treated in the 
different centers included in the studies.  
Demographic features, such as age at disease onset, sex and time to follow-up, are consistent 
with findings in previous studies. (8,25) Most children in this cohort presented initially with fever 
and/or arthritis. Other systemic symptoms such as cutaneous rash, lymphadenopathies, 
organomegalies or serositis were less frequent: these results are in agreement with a 
retrospective observation study that included 136 patients diagnosed with SoJIA from three 
tertiary rheumatology referral centers in the United States of America between 1990 and 2005. 
(8)  
Strikingly, the results of our study show that a longer delay to diagnosis was associated with a 
poorer outcome (i.e. a persistent disease evolution). This finding contrasts with the observation 
by the cohort study of Janow et al., where data on 372 SoJIA patients were collected through 
convenience sampling between 2010 and 2013 in 62 participating centers of the United States 
of America and Canada. They observed a shorter delay from symptom onset to diagnosis for 
patients with a chronic course of disease. (29) This inconsistency may be due to the difference 
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in the definition of the persistent disease evolution group by the two studies. Janow et al. 
identified a sub group called “persistent arthritis only” where only children with arthritis (i.e. 
exclusion of patients with systemic symptoms at time point “enrollment”) and an active disease 
over two years were included. Comparison is therefore difficult as in our study, patients with 
active disease over two years with either elevated laboratory markers, systemic or articular 
symptoms were classified in the persistent group. To the best of our knowledge, our study is 
the first to demonstrate a possible association between a longer delay to diagnosis (> 2 
months) and the outcome of a persistent disease evolution. In consideration of the framework 
and limitations of this study (named further below), no theory is known to support this finding 
and only hypotheses on the possible reasons can be formulated. One hypothesis that may 
support the finding is known as “the window of opportunity”. In this simplified model, the author 
claims that pro-inflammatory cytokines of the innate immune system (e.g. IL-1β) would activate 
the “antigen-driven T-cell immunity” in a second stage of disease, and thereby promote chronic 
arthritis by adaptive immunity in this well-known autoinflammatory disease. (30) Therefore, it 
is thought that early effective intervention is crucial to interrupt the biphasic process and avoid 
chronic articular disease. A longer period to effective diagnosis may also imply a delay to 
therapy, “the window of opportunity” could be missed and could thus lead to chronic arthritis. 
The results of our study may support some elements of this hypothesis by showing important 
articular involvement in the persistent group at 12 months as well as the risk of having an active 
joint count ≥1 at 72 months at nearly 20%. One could hypothesis, that on target therapy may 
not be enough to achieve inactive disease, as an established disease may result from complex 
immunological pathways and a multitude of cytokines (e.g. IL-1β, IL-6, IL-18, IL-17) implicated 
in the inflammatory process of SoJIA. Therefore, it may be the high complexity of the aberrant 
innate immune system in this pathology rendering therapy and prediction of disease evolution 
difficult, rather than an autoimmune mechanism. (18,31,32)  
Our univariate findings, with the significantly higher frequency of arthritis and the significantly 
higher rate of elevated inflammatory markers during the first year post-diagnosis in the chronic 
disease evolution group, are tendencies that mirror identified predictors by a multiple 
regression model in previous studies. (26,33–35) We could not find any significant difference 
between the persistent and non-persistent groups in the conducted multivariate analysis.  
In 2012, Beukelman et al. reported a higher use of Methotrexate and Ciclosporin in SoJIA 
patients with polyarthritis and children with radiologic damage, respectively. (36) Therefore, an 
important use of DMARDs in the persistent group of this study could retrospectively be 
interpreted as an indirect sign of a greater articular involvement. Nonetheless, the 
interpretation of these results needs to be treated with caution as there was no analysis on 
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confounding factors done. The long treatment duration in the chronic group is interlinked with 
the definition of the group but should also be seen as an evidence of how difficult treatment of 
these chronically affected children is. We also provide evidence that therapeutic strategies 
remain heterogenous and are based on exacerbation if the initial essay is not effective. 
Furthermore, we show that glucocorticoids and NSAID remain important baseline therapies, 
but that biologic agents are faster and more frequently used in the therapeutic procedure due 
to important scientific evidence of their efficacy and safety in SoJIA. (10,12,37,38)  
The probability of attaining inactive disease within the whole study population are consistent 
with earlier findings of a prospective Canadian cohort study published in 2015. In both studies, 
two-thirds of the children suffering from SoJIA achieved inactive disease within two years of 
diagnosis. In the remaining group, a small percentage of patients did not achieve inactive 
disease throughout the whole study period. (39) An outcome that corresponds with the 
persistent disease evolution category in this study.   
In line with our findings, the ability of a rapid decrease of active joint count during first two years 
has been reported by Gunzman et al. in 2015. Nonetheless, as most patients achieve active-
joint-count=0 by 72 months post-diagnosis, there are some children in the persistent disease 
evolution group suffering from remaining active joints underlining the severity and long-lasting 
process of SoJIA creating great morbidity. 
One of the limitations of this study is the non-standardized retrospective data collection due to 
limited time and resources within the framework of this master thesis. Therefore, patients 
included in this study, despite the complete information on disease activity, had nonetheless 
missing information on medication use, such as non-reported glucocorticoid or NSAID therapy, 
missing information on laboratory values as well as missing VAS evaluations by physicians 
and patients. The missing information complicated the multivariate statistical analysis by 
excluding an important number of cases. The multivariate model did not show any statistically 
significant difference between the persistent disease evolution group vs. non-persistent group. 
Therefore, no effective predictor of a chronic disease evolution was identified. Another 
limitation is the classification criteria of patients in the polyphasic disease evolution group, who 
were defined by a relapse of active disease after having achieved inactive disease, making 
comparison difficult between studies that used different remission criteria.  
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In conclusion, we have further validated the existence of three clinically discernable disease 
evolution types in SoJIA, which may be predicted at diagnosis by several clinical and 
demographic features. Further research should concentrate on standardized definitions of 
inactive disease and remission, allowing meaningful meta-analysis. Moreover, prospective 
standardized data collection in multicenter cohort studies are needed to generate enough 
statistical power to confirm or reject the presented tendencies within this study.   
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Annex 
Table 1 of the annex: Analysis of variance (ANOVA): Variables at time point 
“diagnosis” (Groups = Monophasic, polyphasic, persistent) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Splenomegaly  Between Groups .313 2 .156 .954 .394 
Within Groups 6.887 42 .164   
Total 7.200 44    
Serositis  Between Groups .391 2 .196 1.708 .194 
Within Groups 4.809 42 .114   
Total 5.200 44    
 
Joint count during first 6 
months 
Between Groups .439 2 .219 .588 .560 
Within Groups 14.538 39 .373   
Total 14.976 41    
Joint count during disease 
course 
Between Groups .636 2 .318 .975 .387 
Within Groups 12.389 38 .326   
Total 13.024 40    
Enthesitis pain  Between Groups .000 2 .000 . . 
Within Groups .000 34 .000   
Total .000 36    
Arthralgia  Between Groups .975 2 .488 2.024 .149 
Within Groups 7.710 32 .241   
Total 8.686 34    
Systemic features  Between Groups .040 2 .020 .902 .413 
Within Groups .938 42 .022   
Total .978 44    
Fever  Between Groups .040 2 .020 .902 .413 
Within Groups .938 42 .022   
Total .978 44    
Rash  Between Groups .283 2 .142 .612 .547 
Within Groups 9.717 42 .231   
Total 10.000 44    
Lymphadenopathy  Between Groups .036 2 .018 .069 .933 
Within Groups 10.601 41 .259   
Total 10.636 43    
Hepatomegaly  Between Groups .004 2 .002 .012 .988 
Within Groups 6.542 41 .160   
 
 Sum of Squares df Mean Square F Sig. 
Gender Between Groups 1.606 2 .803 3.759 .031 
Within Groups 8.972 42 .214   
Total 10.578 44    
Age (diagnosis) Between Groups 149.556 2 74.778 4.741 .014 
Within Groups 662.420 42 15.772   
Total 811.976 44    
Age (first symptoms) Between Groups 188.350 2 94.175 7.366 .002 
Within Groups 536.940 42 12.784   
Total 725.290 44    
Delay between disease onset 
and diagnosis (months) 
Between Groups 455.037 2 227.519 1.106 .340 
Within Groups 8642.163 42 205.766   
Total 9097.200 44    
Time from diagnosis to 
inactive disease (months) 
 
Between Groups 30426.671 2 15213.336 38.781 .000 
Within Groups 16476.129 42 392.289   
Total 46902.800 44    
ESR (mm/h) Between Groups 43120.382 2 21560.191 .501 .612 
Within Groups 1031877.026 24 42994.876   
Total 1074997.407 26    
CRP (mg/L) Between Groups 22757.950 2 11378.975 2.173 .133 
Within Groups 141377.705 27 5236.211   
Total 164135.655 29    
Arthritis at any moment of the 
disease 
Between Groups .218 2 .109 1.733 .189 
Within Groups 2.578 41 .063   
Total 2.795 43    
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Table 2 of the annex: Analysis of variance (ANOVA): Variables at time point “6 
months” (Groups = Monophasic, polyphasic, persistent) 
 
 
 
 
Table 3 of the annex: Analysis of variance (ANOVA): Variables at time point “12 
months” (Groups = Monophasic, polyphasic, persistent) 
 
 
 
Sum of Squares df Mean Square F Sig. 
Fever  Between Groups .045 2 .023 .475 .629 
Within Groups .909 19 .048   
Total .955 21    
Rash  Between Groups .321 2 .161 1.705 .202 
Within Groups 2.357 25 .094   
Total 2.679 27    
Polyadenopathy  Between Groups .045 2 .022 .563 .577 
Within Groups .917 23 .040   
Total .962 25    
Hepatomegaly  Between Groups .000 2 .000 . . 
Within Groups .000 25 .000   
Total .000 27    
Splenomegaly  Between Groups .000 2 .000 . . 
Within Groups .000 25 .000   
Total .000 27    
Serositis  Between Groups .117 2 .058 1.190 .328 
Within Groups .833 17 .049   
Total .950 19    
Number of active joints Between Groups 30.409 2 15.205 1.279 .297 
 
Within Groups 285.220 24 11.884   
 Total 315.630 26    
Disease activity VAS by 
physician  
Between Groups 70.729 2 35.365 5.081 .021 
 
Within Groups 104.396 15 6.960   
 Total 175.125 17    
ESR (mm/h) Between Groups 1606.617 2 803.308 1.301 .298 
 
Within Groups 10500.333 17 617.667   
 Total 12106.950 19    
CRP (mg/L) Between Groups 3721.354 2 1860.677 .915 .418 
 
Within Groups 38655.704 19 2034.511   
 Total 42377.058 21    
 
 
 Sum of Squares df Mean Square F Sig. 
Fever  Between Groups .679 2 .340 3.188 .058 
Within Groups 2.769 26 .107   
Total 3.448 28    
Rash  Between Groups .268 2 .134 1.182 .318 
Within Groups 4.090 36 .114   
Total 4.359 38    
Polyadenopathy  Between Groups .044 2 .022 .813 .452 
Within Groups .929 34 .027   
Total .973 36    
Hepatomegaly  Between Groups .000 2 .000 . . 
Within Groups .000 35 .000   
Total .000 37    
Splenomegaly  Between Groups .000 2 .000 . . 
Within Groups .000 35 .000   
Total .000 37    
Serositis  Between Groups .000 2 .000 . . 
Within Groups .000 27 .000   
Total .000 29    
Number of active joints Between Groups 113.030 2 56.515 11.940 .000 
Within Groups 146.735 31 4.733   
Total 259.765 33    
Disease activity VAS by 
physician 
Between Groups 160.222 2 80.111 18.679 .000 
Within Groups 85.778 20 4.289   
Total 246.000 22    
ESR (mm/h) Between Groups 8339.744 2 4169.872 5.048 .015 
Within Groups 19826.331 24 826.097   
Total 28166.074 26    
CRP (mg/L) Between Groups 36828.041 2 18414.020 6.727 .004 
Within Groups 79376.929 29 2737.135   
Total 116204.970 31    
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Table 4 of the annex: multivariate logistic regression analysis 
 
Multivariate logistic regression analysis 
 B S.E. Wald df Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
 Delay between disease 
onset and diagnosis > 
2 months 
17.813 10611.307 .000 1 .999 54477052.250 .000 . 
Arthritis at 6 months -46.639 29100.265 .000 1 .999 .000 .000 . 
Oligoarthritis 45.416 16305.213 .000 1 .998 52971699670
000000000.00
0 
.000 . 
ESR > = 26 mm/h at 6 
months 
105.561 17881.534 .000 1 .995 6.993E+45 .000 . 
Arthritis at 12 months 19.557 15886.598 .000 1 .999 311380998.00
0 
.000 . 
VAS patient >= 1 at 12 
months 
-57.109 10386.744 .000 1 .996 .000 .000 . 
ESR > = 26 mm/h at 
12 months 
-16.031 28626.424 .000 1 1.000 .000 .000 . 
CRP > 10 mg/L at 12 
months 
-2.515 8244.323 .000 1 1.000 .081 .000 . 
Disease Modifying 
Anti-Rheumatic Drugs 
-71.620 25244.106 .000 1 .998 .000 .000 . 
DMARD treatment 
duration ≥6 months 
154.794 28006.736 .000 1 .996 1.684E+67 .000 . 
NSAID treatment 
duration ≥6 months 
12.007 11451.269 .000 1 .999 163898.151 .000 . 
Constant -36.256 10622.710 .000 1 .997 .000   
a. Variable(s) entered on step 1: Delay between disease onset and diagnosis > 2 months, Active joint count 
>= 1 at 6 months , Arthritis (Oligo- or Polyarthritis) at 6 months, ESR > = 26 mm/h at 6 months, Active joint 
count >= 1 at 12 months, Arthritis (Oligo- or Polyarthritis) at 12 months, VAS patient >= 1 at 12 months, 
ESR > = 26 mm/h at 12 months, CRP > 10 mg/L at 12 months, Disease Modifying Anti-Rheumatic Drugs, 
DMARD treatment duration ≥6 months, NSAID treatment duration ≥6 months. 
b. B = Intercept; S.E. = Standard Error; Wald = Wald Chi-Square test; df.: degree of freedom of the Wald Chi-
Square test; Sig. = Significance of the Wald Chi-Square test (p < 0.05); Exp(B) = Odds Ratio; C.I. for 
Exp(B) = Confidence Interval 
 
 
